Your browser version may not work well with NCBI's Web applications. More information here...
1: Neuroreport. 2004 Mar 1;15(3):509-13. Links

The role of platelet activating factor in prion and amyloid-beta neurotoxicity.

Bate C, Salmona M, Williams A.

Department of Veterinary Pathology, Glasgow University Veterinary School, Bearsden Road, Glasgow G61 1QH, UK. c.bate@vet.gla.ac.uk

In the prion diseases, neurodegeneration is preceded by the accumulation of the disease-associated isoform of the prion protein (PrP). In the present study, neurones treated with three different phospholipase A2 inhibitors were resistant to the toxic effects of PrP peptides or a synthetic miniprion (sPrP106). Phospholipase A2 inhibitors also protected neurones against a toxic peptide found in Alzheimer's disease (amyloid-beta1-42). Further studies showed that neurones pre-treated with platelet activating factor (PAF) antagonists were equally resistant to PrP peptides or amyloid-beta1-42. Moreover, both phospholipase A2 inhibitors and PAF antagonists reduced the activation of caspase-3, a marker of apoptosis, and the production of prostaglandin E2 that is closely associated with neuronal death in prion or Alzheimer's diseases.

PMID: 15094513 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Dinoprostone (Cervidil® , Prepidil® , Prostin E2® )

    Dinoprostone is used to prepare the cervix for the induction of labor in pregnant women who are at or near term. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

  • Source: AHFS Consumer Medication Information